Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Peg-aspargase, and Anlotinib with Radiotherapy for Early Stage NK/T Cell Lymphoma
NCT03936452Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab and anlotinib in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by Sun Yat-sen University. Started Apr 2019; status: completed.
02
Drugs
sintilimabanlotinib
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT03936452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936452.